Long-term drug survival of secukinumab in real life in the era of novel biologics: a 5-year, retrospective study, including difficult-to-treat areas

J Eur Acad Dermatol Venereol. 2022 Aug;36(8):e626-e627. doi: 10.1111/jdv.18087. Epub 2022 Mar 26.

Authors

E Sotiriou^#¹, K Bakirtzi^#¹, E Vakirlis¹, I Papadimitriou¹, P Eftychidou¹, M Trifona¹, A Lallas¹, D Ioannides¹

Affiliation

¹ First Department of Dermatology and Venereology, Aristotle University Thessaloniki, Thessaloniki, Greece.

^# Contributed equally.

PMID: 35305054
DOI: 10.1111/jdv.18087

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use
Biological Factors / therapeutic use
Biological Products* / therapeutic use
Humans
Psoriasis* / drug therapy
Retrospective Studies
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
Biological Factors
Biological Products
secukinumab